Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.

Drug design, development and therapy - 1 Jan 2017

Audibert Céline, Perlaky Anna, Stuntz Mark, Glass Daniel

Abstract excerpt

BACKGROUND: Advanced ovarian cancer patients have a poor prognosis, mainly because the disease is diagnosed at a late stage. A number of therapeutic approaches, such as neoadjuvant and maintenance therapies, have been developed to try to improve treatment outcome. In parallel, the targeted therapies bevacizumab and olaparib have recently been approved for ovarian cancer treatment. The goal of our survey was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bevacizumab
Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Europe

Share to Health Care Surveys

Share to Ovarian Neoplasms

Share to Phthalazines

Share to Piperazines

Source

Open in PubMed Open full text

Identifiers

PMID: 29255348
DOI: 10.2147/DDDT.S151420
PMCID: PMC5723112

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists.PMID 29255348Read ↗

Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM).Semantic proximity Read ↗

First-Line Maintenance Therapy Patterns in BRCA Wild-Type, HRD-Negative or Biomarker-Unknown Advanced Epithelial Ovarian Cancer: A Five-Country European Real-World Study by APLUSASemantic proximity Read ↗

Study finds different treatment responses between BRCA2- and BRCA1-mutated ovarian cancers.Semantic proximity Read ↗

Characteristics of Patients with Newly Diagnosed High-Grade Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer in 2018–2023 and the Impact of Molecular Diagnostics on the Chemotherapy in Clinical PracticeSemantic proximity Read ↗

Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.Semantic proximity Read ↗

Health-Related Quality of Life in PARP-Inhibitor Olaparib Maintenance in Ovarian Cancer Patients: Real World Data and Experience of a Single-Center in ChinaSemantic proximity Read ↗

Ovarian Cancer in the Era of Immune Checkpoint Inhibitors: State of the Art and Future Perspectives.Semantic proximity Read ↗

Challenges That Hinder the Translation of Clinical Advances Into Practice: Results From an International Assessment in Colorectal Cancer.Semantic proximity Read ↗

Experiencia con el uso de olaparib en pacientes con cáncer de ovario.Semantic proximity Read ↗

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Semantic proximity Read ↗

First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter studySemantic proximity Read ↗

Olaparib and advanced ovarian cancer: Summary of the past and looking into the futureSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.